53 results
8-K
EX-1.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
writing prospectus provided in connection with this offering. Neither we nor the underwriters take any responsibility for, and provide no assurance … not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. You should not assume … in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
8-K
EX-3.1
5ik udlymycmfacct
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:07pm
8-K
EX-10.1
5kq 9rht76t5nn5
8 Jul 22
Nurix Therapeutics Announces $55 Million Registered Direct Offering
4:13pm
424B5
nqth24n
8 Jul 22
Prospectus supplement for primary offering
4:10pm
424B5
nvsa mudq
8 Jul 22
Prospectus supplement for primary offering
4:09pm